Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director | June 01, 2026 | June 03, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, Chief Reg. Affairs | February 25, 2021 | March 02, 2021 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Dev. Op. Officer | June 13, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-06-01 | Direct | 40,412 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 40,412 · Balance 40,412 F1: Scheduled to vest in four equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Scheduled to vest in four equal quarterly installments.
Karyopharm Therapeutics Inc.
Report date February 25, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,401 |
Reported balance
After 2021-02-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-25 · Grant · Acquired 22,013 · Balance 45,401 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 19,245 RSUs previously reported in Table II, and 4,143 shares of common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2031-02-24 | Direct | 59,968 |
Reported balance
After 2021-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-25 · Grant · Acquired 59,968 · Balance 59,968 F3: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.
F2: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 19,245 RSUs previously reported in Table II, and 4,143 shares of common stock.
F3: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Replimune Group, Inc.
Report date June 13, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,110 |
Reported balance
After 2023-06-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-13 · Sale · Disposed 12,043 · Balance 136,110 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.59 to $24.57. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 135,293 |
Reported balance
After 2023-06-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-06-13 · Sale · Disposed 817 · Balance 135,293 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.34 to $23.55. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4: Following the sales reported on this form 4, the reporting person continues to beneficially own 135,293 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 248,750 shares of the Issuer's common stock, 80,259 of which are exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.59 to $24.57. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.34 to $23.55. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Following the sales reported on this form 4, the reporting person continues to beneficially own 135,293 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 248,750 shares of the Issuer's common stock, 80,259 of which are exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 21:26 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 40,412 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001451038-26-000002 · form4-06032026_090650.xml · derivative · entry 1 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,412 Underlying: Voting Common Shares · 40,412 shares Expires 2036-06-01 F1 · derivative.exercise_date: Scheduled to vest in four equal quarterly installments. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:17 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 32,162 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001437749-25-019292 · rdgdoc.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,162 Underlying: Common Shares · 32,162 shares Expires 2035-05-31 F1 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:14 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000046 · primary_doc.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 817 | $23.45 | $19,158.65 |
DisclosureSEC source: 0001104659-23-071774 · tm2318878-2_4seq1.xml · nonDerivative · entry 2 Lewis Tanya · CIK 0001451038 · Chief Dev. Op. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,293 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.34 to $23.55. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this form 4, the reporting person continues to beneficially own 135,293 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 248,750 shares of the Issuer's common stock, 80,259 of which are exercisable as of the date hereof. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 12,043 | $24.10 | $290,236.30 |
DisclosureSEC source: 0001104659-23-071774 · tm2318878-2_4seq1.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · Chief Dev. Op. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,110 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.59 to $24.57. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:13 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 7,493 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000057 · primary_doc.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,493 Underlying: Common Shares · 7,493 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:34 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 12,207 | $18.05 | $220,336.35 |
DisclosureSEC source: 0001104659-23-062376 · tm2316199-7_4seq1.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · Chief Dev. Op. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,153 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041720 · tm2311410-4_4seq1.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Chief Dev. Op. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041720 · tm2311410-4_4seq1.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · Chief Dev. Op. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,360 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 01, 2023 Filed Mar 6, 2023 22:14 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock option (right to buy) · Derivative | 26,443 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001235802-23-000029 · primary_doc.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,443 Underlying: Common Shares · 26,443 shares Expires 2033-02-28 F1 · derivative.exercise_date: Vests in 12 nearly equal quarterly installments over three years. Read SEC document |
| May 16, 2022 Filed May 18, 2022 23:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,473 | $14.59 | $79,851.07 |
DisclosureSEC source: 0001104659-22-062608 · tm2215879-5_4seq1.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · Chief Dev. Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,360 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.59 to $14.62. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 78,750 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042765 · tm2211665-5_4seq1.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Chief Dev.Op Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2032-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042765 · tm2211665-5_4seq1.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · Chief Dev.Op Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,833 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| May 10, 2021 Filed May 12, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $33.99 | $0.00 |
DisclosureSEC source: 0001104659-21-064730 · tm2115949-1_4seq1.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Chief Dev. Oper. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-05-10 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on May 10, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| May 10, 2021 Filed May 12, 2021 01:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 73,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-064730 · tm2115949-1_4seq1.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · Chief Dev. Oper. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,333 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:14 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046724 · tm2112099-6_4seq1.xml · derivative · entry 1 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:13 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015485 · doc4.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Common Stock · 59,968 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:13 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015485 · doc4.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,401 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 19,245 RSUs previously reported in Table II, and 4,143 shares of common stock. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 23:49 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,046 | $15.52 | $31,752.08 |
DisclosureSEC source: 0001209191-21-011496 · doc4.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,143 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 5,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009081 · doc4.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,950 Underlying: Common Stock · 5,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F2 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 01:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009081 · doc4.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · EVP, Chief Reg. Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:07 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $42.00 | $0.00 |
DisclosureSEC source: 0001104659-20-120937 · a4.xml · derivative · entry 1 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2030-11-02 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on November 2, 2021, and the remainder of the shares underlying this stock option vest in 24 approximately equal monthly installments thereafter. Read SEC document |
| October 30, 2020 Filed Nov 5, 2020 01:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 226 | $15.58 | $3,521.08 |
DisclosureSEC source: 0001209191-20-057054 · doc4.xml · nonDerivative · entry 2 Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539 F2 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 28, 2020 Filed Nov 5, 2020 01:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 765 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-057054 · doc4.xml · derivative · entry 3 Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,295 Underlying: Common Stock · 765 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On October 28, 2019, the reporting person was granted 3,060 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on October 28, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: On October 28, 2019, the reporting person was granted 3,060 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on October 28, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| October 28, 2020 Filed Nov 5, 2020 01:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 765 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-057054 · doc4.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 22,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007515 · doc4.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 Underlying: Common Stock · 22,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 60,600 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007515 · doc4.xml · derivative · entry 1 Lewis Tanya · CIK 0001451038 · EVP,Chief Reg.&Quality Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,600 Underlying: Common Stock · 60,600 shares Expires 2030-02-04 F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.